ProCE Banner Activity

Phase Ib Study: Venetoclax With or Without Azacitidine for Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Slideset Download
Conference Coverage
Venetoclax alone or in combination with azacitidine was well tolerated in patients with relapsed/refractory MDS, with combination therapy achieving an ORR of 40% and estimated 12-month OS of 65%.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company